TapewireFind a company

person · Reporting owner

Barnett Eva Renee

Disclosed activity across 1 company

Tapewire entity
80701
SEC CIK
0001883766

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Immunovant, Inc.IMVT · Entity 3632Chief Financial OfficerApril 16, 2025April 17, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Immunovant, Inc.

Report date April 16, 2025 · Filed April 17, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect396,774 Reported balance After 2025-04-16 transaction · row 1
1 source row

Row 1 · 2025-04-16 · Sale · Disposed 2,993 · Balance 396,774

F1: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on April 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.74 - $15.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Filing footnotes · ownership attribution and instrument terms

F1: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on April 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.74 - $15.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
April 16, 2025 Filed Apr 17, 2025 20:08 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 2,993 $14.89 $44,565.77
Disclosure

SEC source: 0001764013-25-000076 · wk-form4_1744920500.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 396,774

F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on April 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.74 - $15.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 09, 2025 Filed Apr 11, 2025 20:06 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 4,050 $12.99 $52,609.50
Disclosure

SEC source: 0001764013-25-000067 · wk-form4_1744401967.xml · nonDerivative · entry 2

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 399,767

F3 · shares: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,938 of these RSUs vested on April 4, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.75 - $13.26 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 09, 2025 Filed Apr 11, 2025 20:06 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 7,013 $12.99 $91,098.87
Disclosure

SEC source: 0001764013-25-000067 · wk-form4_1744401967.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 403,817

F1 · shares: On April 2, 2024, the holder was granted 54,978 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 4, 2024, of which 13,744 of these RSUs vested on April 2, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.75 - $13.26 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:48 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 125,180 $0.00 Strike: $15.20 $0.00
Disclosure

SEC source: 0001764013-25-000051 · wk-form4_1743713294.xml · derivative · entry 2

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,180

Underlying: Common Stock · 125,180 shares

Expires 2035-04-01

F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 1, 2026 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:48 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 88,878 $0.00 $0.00
Disclosure

SEC source: 0001764013-25-000051 · wk-form4_1743713294.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 410,830

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 1, 2026, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
February 19, 2025 Filed Feb 21, 2025 21:05 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 2,814 $20.86 $58,700.04
Disclosure

SEC source: 0001764013-25-000031 · wk-form4_1740171904.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 321,952

F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on February 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.51 - $21.09 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 15, 2025 Filed Jan 17, 2025 21:05 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 109 $24.19 $2,636.71
Disclosure

SEC source: 0001764013-25-000014 · wk-form4_1737147952.xml · nonDerivative · entry 2

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 324,766

F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on January 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.13 - $24.21 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 15, 2025 Filed Jan 17, 2025 21:05 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 2,189 $23.81 $52,120.09
Disclosure

SEC source: 0001764013-25-000014 · wk-form4_1737147952.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 324,875

F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on January 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.13 - $24.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 08, 2025 Filed Jan 10, 2025 21:12 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 4,105 $24.10 $98,930.50
Disclosure

SEC source: 0001764013-25-000004 · wk-form4_1736543549.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 327,064

F1 · shares: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,937 of these RSUs vested on January 4, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.91 - $24.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
November 20, 2024 Filed Nov 22, 2024 21:09 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 4,174 $25.45 $106,228.30
Disclosure

SEC source: 0001764013-24-000194 · wk-form4_1732309782.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 331,169

F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.91 - $25.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
October 16, 2024 Filed Oct 18, 2024 20:27 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 3,271 $28.79 $94,172.09
Disclosure

SEC source: 0001764013-24-000171 · wk-form4_1729283253.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 335,343

F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on October 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.31 - $29.14 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
October 09, 2024 Filed Oct 11, 2024 20:04 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 5,162 $29.56 $152,588.72
Disclosure

SEC source: 0001764013-24-000166 · wk-form4_1728677055.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 338,614

F1 · shares: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,938 of these RSUs vested on October 4, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.28 - $29.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
August 21, 2024 Filed Aug 23, 2024 20:11 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 149 $32.32 $4,815.68
Disclosure

SEC source: 0001764013-24-000158 · wk-form4_1724443899.xml · nonDerivative · entry 2

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 343,776

F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on August 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.28 - $32.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
August 21, 2024 Filed Aug 23, 2024 20:11 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 3,619 $31.84 $115,228.96
Disclosure

SEC source: 0001764013-24-000158 · wk-form4_1724443899.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 343,925

F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on August 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 - $32.25 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
July 17, 2024 Filed Jul 19, 2024 21:39 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 184 $30.55 $5,621.20
Disclosure

SEC source: 0001764013-24-000135 · wk-form4_1721425179.xml · nonDerivative · entry 2

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 347,544

F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on July 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 - $30.84 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
July 17, 2024 Filed Jul 19, 2024 21:39 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 2,939 $29.64 $87,111.96
Disclosure

SEC source: 0001764013-24-000135 · wk-form4_1721425179.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 347,728

F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on July 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 - $30.28 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
July 09, 2024 Filed Jul 10, 2024 21:07 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 4,747 $28.06 $133,200.82
Disclosure

SEC source: 0001764013-24-000127 · wk-form4_1720645649.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 350,667

F1 · shares: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,937 of these RSUs vested on July 4, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.48 - $28.42 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
May 22, 2024 Filed May 24, 2024 20:18 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 4,042 $29.65 $119,845.30
Disclosure

SEC source: 0001764013-24-000099 · wk-form4_1716581887.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 355,414

F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on May 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.31 - $30.02 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 17, 2024 Filed Apr 19, 2024 22:01 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 2,774 $29.94 $83,053.56
Disclosure

SEC source: 0001764013-24-000079 · wk-form4_1713564051.xml · nonDerivative · entry 2

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 359,456

F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 21,916 of these RSUs vested on April 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.43 - $30.20 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 17, 2024 Filed Apr 19, 2024 22:01 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 9,479 $28.80 $272,995.20
Disclosure

SEC source: 0001764013-24-000079 · wk-form4_1713564051.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 362,230

F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 21,916 of these RSUs vested on April 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.43 - $29.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 09, 2024 Filed Apr 10, 2024 20:18 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 3,689 $31.18 $115,023.02
Disclosure

SEC source: 0001764013-24-000073 · wk-form4_1712780298.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 371,709

F1 · shares: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,938 of these RSUs vested on April 4, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.73 - $31.45 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 02, 2024 Filed Apr 4, 2024 20:27 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 68,723 $0.00 Strike: $30.78 $0.00
Disclosure

SEC source: 0001764013-24-000046 · wk-form4_1712262419.xml · derivative · entry 2

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,723

Underlying: Common Stock · 68,723 shares

Expires 2034-04-02

F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 2, 2025 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
April 02, 2024 Filed Apr 4, 2024 20:27 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 54,978 $0.00 $0.00
Disclosure

SEC source: 0001764013-24-000046 · wk-form4_1712262419.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 375,398

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 2, 2025, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
February 22, 2024 Filed Feb 23, 2024 21:21 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 2,930 $36.15 $105,919.50
Disclosure

SEC source: 0001764013-24-000041 · wk-form4_1708723240.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 320,420

F1 · security: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on February 17, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.85 - $36.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 11, 2024 Filed Jan 12, 2024 21:34 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 834 $42.43 $35,386.62
Disclosure

SEC source: 0001764013-24-000010 · wk-form4_1705095240.xml · nonDerivative · entry 2

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 323,350

F1 · security: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,937 of these RSUs vested on January 4, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $42.17 - $42.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 11, 2024 Filed Jan 12, 2024 21:34 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 2,681 $41.64 $111,636.84
Disclosure

SEC source: 0001764013-24-000010 · wk-form4_1705095240.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 324,184

F1 · security: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,937 of these RSUs vested on January 4, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.06 - $42.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
November 22, 2023 Filed Nov 24, 2023 19:51 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 154 $33.52 $5,162.08
Disclosure

SEC source: 0001764013-23-000144 · wk-form4_1700855509.xml · nonDerivative · entry 2

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 326,865

F1 · security: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $33.46 - $33.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
November 22, 2023 Filed Nov 24, 2023 19:51 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 3,901 $32.75 $127,757.75
Disclosure

SEC source: 0001764013-23-000144 · wk-form4_1700855509.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 327,019

F1 · security: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $32.43 - $33.38 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
October 10, 2023 Filed Oct 11, 2023 20:11 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 4,557 $36.92 $168,244.44
Disclosure

SEC source: 0001764013-23-000120 · wk-form4_1697055061.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 330,920

F1 · security: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,938 of these RSUs vested on October 4, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $36.92 - $36.97 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
August 24, 2023 Filed Aug 25, 2023 21:03 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 1 $20.89 $20.89
Disclosure

SEC source: 0001764013-23-000103 · wf-form4_169299740413055.xml · nonDerivative · entry 2

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 335,477

F1 · security: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on August 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

Read SEC document
August 24, 2023 Filed Aug 25, 2023 21:03 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 14,385 $20.30 $292,015.50
Disclosure

SEC source: 0001764013-23-000103 · wf-form4_169299740413055.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 335,478

F1 · security: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on August 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.87 - $20.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
July 19, 2023 Filed Jul 20, 2023 20:35 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 2,725 $24.94 $67,961.50
Disclosure

SEC source: 0001764013-23-000080 · wf-form4_168988534195460.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 349,863

F1 · security: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,937 of these RSUs vested on July 4, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

Read SEC document
April 18, 2023 Filed Apr 19, 2023 20:15 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 3,423 $15.27 $52,269.21
Disclosure

SEC source: 0001764013-23-000053 · wf-form4_168193529586441.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 352,588

F1 · security: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,938 of these RSUs vested on April 4, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.08 - $15.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 12, 2023 Filed Apr 14, 2023 20:22 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 113,821 $0.00 Strike: $14.70 $0.00
Disclosure

SEC source: 0001764013-23-000040 · wf-form4_168150372133037.xml · derivative · entry 2

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,821

Underlying: Common Stock · 113,821 shares

Expires 2033-04-12

F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on April 12, 2024 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

Read SEC document
April 12, 2023 Filed Apr 14, 2023 20:22 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 87,664 $0.00 $0.00
Disclosure

SEC source: 0001764013-23-000040 · wf-form4_168150372133037.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 356,011

F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on April 12, 2024 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

Read SEC document
January 11, 2023 Filed Jan 13, 2023 13:16 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 4,499 $16.75 $75,358.25
Disclosure

SEC source: 0001764013-23-000008 · wf-form4_167361579253284.xml · nonDerivative · entry 2

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 268,347

F1 · security: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,937 of these RSUs vested on January 4, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.31 - $16.80 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 11, 2023 Filed Jan 13, 2023 13:16 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 11 $15.15 $166.65
Disclosure

SEC source: 0001764013-23-000008 · wf-form4_167361579253284.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,846

F1 · security: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,937 of these RSUs vested on January 4, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

Read SEC document
October 11, 2022 Filed Oct 13, 2022 20:20 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 12,500 $9.44 $118,000.00
Disclosure

SEC source: 0001764013-22-000128 · wf-form4_166569241491854.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,857

F1 · security: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 25% of these RSUs vested on October 4, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs.

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.16 - $9.44 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
August 17, 2022 Filed Aug 19, 2022 20:52 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 169,648 $0.00 Strike: $4.99 $0.00
Disclosure

SEC source: 0001764013-22-000101 · wf-form4_166094233293811.xml · derivative · entry 2

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,648

Underlying: Common Stock · 169,648 shares

Expires 2032-08-17

F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on August 17, 2023 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

Read SEC document
August 17, 2022 Filed Aug 19, 2022 20:52 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 112,816 $0.00 $0.00
Disclosure

SEC source: 0001764013-22-000101 · wf-form4_166094233293811.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 285,357

F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on August 17, 2023 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

Read SEC document
January 07, 2022 Filed Jan 11, 2022 15:53 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 29,959 $7.25 $217,202.75
Disclosure

SEC source: 0001764013-22-000011 · wf-form4_164191639600365.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,541

F1 · security: On October 4, 2021, the holder was granted 59,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 5, 2021. These RSUs vested in their entirety on January 1, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of these RSUs.

Read SEC document
October 15, 2021 Filed Oct 18, 2021 21:11 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 333,000 $0.00 Strike: $8.72 $0.00
Disclosure

SEC source: 0001764013-21-000108 · wf-form4_163459145674723.xml · derivative · entry 2

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 333,000

Underlying: Common Stock · 333,000 shares

Expires 2031-10-15

F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on October 4, 2022 and the remainder of the shares underlying the options vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

Read SEC document
October 15, 2021 Filed Oct 18, 2021 21:11 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 143,000 $0.00 $0.00
Disclosure

SEC source: 0001764013-21-000108 · wf-form4_163459145674723.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 202,500

F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on October 4, 2022 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

Read SEC document
October 04, 2021 Filed Oct 5, 2021 16:07 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 59,500 $0.00 $0.00
Disclosure

SEC source: 0001764013-21-000106 · wf-form4_163345002882992.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,500

F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2 · shares: The RSUs vest in their entirety on January 1, 2022, subject to the Reporting Person providing continuous service to the Issuer as of such date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.